Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 39, Issue 2, Pages 137-147
Publisher
Wiley
Online
2013-11-20
DOI
10.1111/apt.12551
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives
- (2015) Chen-Hua Liu et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Systematic review: Asian patients with chronic hepatitis C infection
- (2013) L. H. Nguyen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL28Bpolymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5: Table 1
- (2012) Nabil Antaki et al. GUT
- A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C
- (2012) Pham Thi Thu Thuy et al. JOURNAL OF HEPATOLOGY
- Treatment Results of Chronic Hepatitis C Genotype 5 and 6 Infections in Germany
- (2012) S. Mauss et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Systematic review: epidemiology of hepatitis C genotype 6 and its management
- (2011) D. T. Chao et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- IL-28B predicts response to chronic hepatitis C therapy - fine-mapping and replication study in Asian populations
- (2011) H. Ochi et al. JOURNAL OF GENERAL VIROLOGY
- 1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12
- (2011) S. Zeuzem et al. JOURNAL OF HEPATOLOGY
- IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
- (2011) Tarik Asselah et al. JOURNAL OF HEPATOLOGY
- Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: A meta-analysis of two large prospective clinical trials
- (2011) François D'Heygere et al. JOURNAL OF MEDICAL VIROLOGY
- Hepatitis C virus genotyping in Greece: Unexpected high prevalence of genotype 5a in a Greek island
- (2011) Stylianos Karatapanis et al. JOURNAL OF MEDICAL VIROLOGY
- A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
- (2011) William Sievert et al. LIVER INTERNATIONAL
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
- (2011) Markus Cornberg et al. LIVER INTERNATIONAL
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
- (2010) Alexander J. Thompson et al. GASTROENTEROLOGY
- Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6
- (2010) Khoa D. Lam et al. HEPATOLOGY
- Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans
- (2010) Nghia H. Nguyen et al. Hepatology International
- Natural history of chronic hepatitis C: Genotype 1 versus genotype 6
- (2010) Wai-Kay Seto et al. JOURNAL OF HEPATOLOGY
- The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients
- (2009) Robert Flisiak et al. HEPATOLOGY
- Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1
- (2009) Owen T-Y Tsang et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Entire genome sequences of two new HCV subtypes, 6r and 6s, and characterization of unique HVR1 variation patterns within genotype 6
- (2009) C. Li et al. JOURNAL OF VIRAL HEPATITIS
- The global burden of hepatitis C
- (2009) Daniel Lavanchy LIVER INTERNATIONAL
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
- (2009) David L. Thomas et al. NATURE
- Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4
- (2008) J. F. ROSSIGNOL et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Higher Rate of Sustained Virologic Response in Chronic Hepatitis C Genotype 6 Treated With 48 Weeks Versus 24 Weeks of Peginterferon Plus Ribavirin
- (2008) Mindie H. Nguyen et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province
- (2008) N. ANTAKI et al. EPIDEMIOLOGY AND INFECTION
- Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin
- (2008) Jean–François Rossignol et al. GASTROENTEROLOGY
- Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0
- (2008) J. Verbeeck et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin
- (2008) James Fung et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5
- (2008) N. Antaki et al. JOURNAL OF VIRAL HEPATITIS
- Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication
- (2007) Brent E. Korba et al. ANTIVIRAL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search